Gene · 3804
KIR2DL3: killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. KIR2DL3: killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3. Genes, record 3804. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3804
On this page
Gene
- Aliases
- CD158B2, CD158b, GL183, KIR-023GB, KIR-K7b, KIR-K7c, KIR2DL, KIRCL23, NKAT, NKAT-2, NKAT2, NKAT2A, NKAT2B, cl-6, nkat2, nkat2a, nkat2b, p58
- NCBI Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P43628 | Killer cell immunoglobulin-like receptor 2DL3 | 341 | 3 | Ensembl, GeneID, HGNC |
Source UniProt
Patents84
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 50750 | P43628 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 6722 | P43628 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2298 | P43628 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2298 | P43628 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 6722 | P43628 | Espacenet |
| JP 2025081298 A | 2025-05-27 | 345 | P43628 | Espacenet |
| KR 1020250067191 A | 2025-05-14 | 345 | P43628 | Espacenet |
| US 11981731 B2 | 2024-05-14 | 345 | P43628 | Espacenet |
| US 11919946 B2 | 2024-03-05 | 55 | P43628 | Espacenet |
| KR 1020230149327 A | 2023-10-26 | 345 | P43628 | Espacenet |
1 to 10 of 84
See all 84 patentsDrugs2
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
Trials14
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT03347123 | LIRILUMAB | PHASE1/PHASE2 | 2022-02-28 | ClinicalTrials.gov |
| NCT03341936 | LIRILUMAB | PHASE2 | 2022-06-16 | ClinicalTrials.gov |
| NCT02813135 | LIRILUMAB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT02599649 | LIRILUMAB | PHASE2 | 2020-01-06 | ClinicalTrials.gov |
| NCT02481297 | LIRILUMAB | PHASE2 | 2020-05-26 | ClinicalTrials.gov |
| NCT02399917 | LIRILUMAB | PHASE2 | 2019-09-24 | ClinicalTrials.gov |
| NCT02252263 | LIRILUMAB | PHASE1 | ClinicalTrials.gov | |
| NCT01687387 | LIRILUMAB | PHASE2 | 2019-02-08 | ClinicalTrials.gov |
| NCT01592370 | LIRILUMAB | PHASE1/PHASE2 | 2022-02-17 | ClinicalTrials.gov |
| NCT01256073 | IPH-2101 | PHASE1 | ClinicalTrials.gov |
1 to 10 of 14
See all 14 trialsNIH grants1,324
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | KIR2DL3 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 25 | 2025 |
| T32AI007290 | Molecular and Cellular Immunobiology | 23 | 2025 |
| P01CA111412 | NK cells, their receptors and cancer therapy | 21 | 2025 |
| U01AI090905 | Insights Into Immune-Related Diseases Born from Population Genomics | 17 | 2025 |
| ZIABC010791 | Effects of genetic polymorphism in MHC, KIR, and related loci on human disease | 15 | 2025 |
| P01CA065493 | Off-the-Shelf Immune Effector Cells for Hematological Malignancies | 14 | 2025 |
| U01AI069197 | Hematopoietic Stem Cell And Cord Blood Transplantation | 12 | 2025 |
| R01AI128775 | Integrated Exchange and Storage of Current- and Future-Generation Immunogenomic Data | 10 | 2025 |
| P30CA077598 | Cancer Center Support Grant | 9 | 2025 |
| ZIABC010792 | Molecular genetics and population studies of the KIR and HLA gene complexes | 9 | 2025 |
1 to 10 of 1,324Source NIH's project files
See all 1,324 nih grantsPapers2,392
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Prognostic value and immune landscape implications of using a novel homologous recombination repair pathway signature in prostate cancer: A retrospective cohort study. | J Int Med Res | 2026 | 42754412 | PubTator, text mining | PubMed |
| Computational Analysis of Endothelial Cell-related Genes in Ovarian Cancer and Preliminary in vitro Validation of COL1A1. | Curr Med Chem | 2026 | 42517396 | PubTator, text mining | PubMed |
| Flow Cytometric Detection of NK Cell KIR Receptors: a Novel Tool for Functional Profiling in Reproductive Failure. | Clin Lab | 2026 | 42411671 | PubTator, text mining | PubMed |
| Integrative Analysis Reveals BPTF, COL1A1, and COL4A2 as Fibroblast-Related Biomarkers Associated with Immune Infiltration in Ovarian Cancer. | Curr Med Chem | 2026 | 42381315 | PubTator, text mining | PubMed |
| Emphysema Shapes a Pro-Inflammatory Immune Microenvironment in Pulmonary Adenocarcinoma: A Pilot Immune Transcriptomic Profiling Study. | Int J Mol Sci | 2026 | 42123542 | PubTator, text mining | PubMed |
| Functional heterogeneity of γδ T cells in colorectal cancer. | Front Immunol | 2026 | 41953027 | PubTator, text mining | PubMed |
| Transcriptomic Determinants of Circulating Immunity Predict Immune-Related Adverse Events (irAEs) in Cancer Patients Receiving PD-1/PD-L1 Blockade. | Thorac Cancer | 2026 | 41920053 | PubTator, text mining | PubMed |
| Multi‑omics and their integration in psoriasis research (Review). | Mol Med Rep | 2026 | 41891974 | PubTator, text mining | PubMed |
| Molecular signatures and causal factors underlying latent cytomegalovirus infection among people living with HIV (PLHIV). | Nat Commun | 2026 | 41881997 | PubTator, text mining | PubMed |
| Dynamic Allostery in T Cell Receptor Specificity: A Role for Peptides and MHC Polymorphisms in Allosterically Tuning Immune Recognition. | Bioessays | 2026 | 41879488 | PubTator, text mining | PubMed |
1 to 10 of 2,392
See all 2,392 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3804
GET https://conductscience.org/api/genes/v1/3804/patents?page=2